The difficile clostridium;Das difficile clostridium

LaboratoriumsMedizin

Volumn 32, Issue 4, 2008, Pages 219-234

  Von Eichel Streiber, Christoph ^a,c   Braun, Veit ^b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b tgcBIOMICS GmbH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

027 ribotype; Antibiotic; Clostridium difficile (CDAD); Cytotoxin; Diarrhea; Enterotoxin; Hypervirulent isolates; Obligation to report; Pseudomembranous colitis

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; ENTEROTOXIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; MEZLOCILLIN; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TICARCILLIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; EPIDEMIC; HOSPITAL; HUMAN; INFECTIOUS DIARRHEA; OUTPATIENT; PSEUDOMEMBRANOUS COLITIS; REVIEW;

CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE;

EID: 48249086116     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2008.043     Document Type: Review

References (71)

1. Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev 1993;6:251-65.
2. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974;81:429-33.
3. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxinproducing clostridia. N Engl J Med 1978;298:531-4.
4. Rifkin GD, Fekety FR, Silva J Jr. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 1977;2:1103-6.
5. Larson HE, Price AB. Pseudomembranous colitis: presence of clostridial toxin. Lancet 1977;2:1312-4.
6. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxinproducing clostridia. N Engl J Med 1978;298:531-4.
7. George RH, Symonds JM, Dimock F, Brown JD, Arabi Y, Shinagawa N, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J 1978;1:695.
8. McFarland LV. Update on the changing epidemiology of Clostridium difficile - associated disease. Nat Clin Pract Gastroenterol Hepatol 2008;5:40-8.
9. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile - associated diarrhea: a review. Arch Intern Med 2001;161:525-33.
10. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
11. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-5.
12. Cunningham R. Proton pump inhibitors and the risk of Clostridium difficile-associated disease: further evidence from the community. CMAJ 2006;175:757.
13. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;8:2442-9.
14. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
15. Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12 Suppl 6:2-18.
16. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006;73:187-97.
17. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection 2007;35:300-7.
18. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008;5:40-8.
19. Riley TV, Codde JP, Rouse IL. Increased length of hospital stay due to Clostridium difficile associated diarrhoea. Lancet 1995;345:455-6.
20. MacGowan AP, Feeney R, Brown I, McCulloch SY, Reeves DS, Lovering AM. Health care resource utilization and antimicrobial use in elderly patients with community-acquired lower respiratory tract infection who develop Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1997;39:537-41.
21. Zaiss NH, Weile J, Ackermann G, Kuijper E, Witte W, Nüebel U. A case of Clostridium difficile-associated disease due to the highly virulent clone of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro Surveill 2007;12:E071115.1.
22. Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B, Küehnen E, et al. Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill 2007;12:E071115.2.
23. www-Seite zu googlen über die Suche nach: RKI Clostridium difficile und Meldepflicht http://www.rki.de/ cln_049/nn_717602/DE/Content/InfAZ/C/ Clostridium_difficile/ Flussdiagramm_Meldung,templateId=raw,property= publicationFile. pdf/Flussdiagramm_Meldung.pdf.
24. Finney JM. Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp 1893,4:53-5.
25. Hall IC, O'Toole E. Intestinal flora in new-born infants. Am J Dis Child 1935;49:390-402.
26. George WL, Sutter VL, Citron D, Finegold SM. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979;9:214-9.
27. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 1983;147:733-6.
28. Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol 2005;54:113-7.
29. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992-8.
30. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl 1:S12-8.
31. Perelle S, Gibert M, Bourlioux P, Corthier G, Popoff MR. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect Immun 1997;65:1402-7.
32. Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 1996;181:29-38.
33. Braun V, von Eichel-Streiber C. Virulence-associated mobile elements in Bacilli and Clostridia. In Pathogenicity Islands and Other Mobile Virulence Elements, Eds Kaper JB und Hacker J. American Society for Microbiology Washington DC 1999.
34. Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001;98:5844-9.
35. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007;64:1274-88.
36. Carter GP, Purdy D, Williams P, Minton NP. Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. J Med Microbiol 2005;54:119-27.
37. Tan KS, Wee BY, Song KP. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 2001;50:613-9.
38. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002;40:3470-5.
39. von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M. Large clostridial cytotoxins - a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol 1996;4:375-82.
40. Amimoto K, Noro T, Oishi E, Shimizu M. A novel toxin homologous to large clostridial cytotoxins found in culture supernatant of Clostridium perfringens type C. Microbiology 2007;153:1198-206.
41. von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet 1992;233:260-8.
42. Rupnik M, Pabst S, Rupnik M, von Eichel-Streiber C, Urlaub H, Söling HD. Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 2005;151:199-208.
43. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995;375:500-3.
44. von Eichel-Streiber C, Meyer zu Heringdorf D, Habermann E, Sartingen S. Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol 1995;17:313-21.
45. Fiorentini C, Fabbri A, Falzano L, Fattorossi A, Matarrese P, Rivabene R, et al. Clostridium difficile toxin B induces apoptosis in intestinal cultured cells. Infect Immun 1998;66:2660-5.
46. Nusrat A, von Eichel-Streiber C, Turner JR, Verkade P, Madara JL, Parkos CA. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001;69:1329-36.
47. Belyi Y, Tabakova I, Stahl M, Aktories K. Lgt: a family of cytotoxic glucosyltransferases produced by Legionella pneumophila. J Bacteriol 2008;190:3026-35.
48. Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, Aktories K, et al. Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem 2003;278:44535-41.
49. Teneberg S, Lönnroth I, Torres López JF, Galili U, Halvarsson MO, Angström J, et al. Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor. Glycobiology 1996;6:599-609.
50. Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol 2006;13:460-1.
51. Flores-Díaz M, Alape-Girón A, Persson B, Pollesello P, Moos M, von Eichel-Streiber C, et al. Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene. J Biol Chem 1997;272:23784-91.
52. von Eichel-Streiber C, Warfolomeow I, Knautz D, Sauerborn M, Hadding U. Morphological changes in adherent cells induced by Clostridium difficile toxins. Biochem Soc Trans 1991;19:1154-60.
53. Florin I, Thelestam M. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb Pathog 1986;1:373-85.
54. Henriques B, Florin I, Thelestam M. Cellular internalisation of Clostridium difficile toxin A. Microb Pathog 1987;2:455-63.
55. Reineke J, Tenzer S, Rupnik M, Koschinski A, Hasselmayer O, Schrattenholz A, et al. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 2007;446:415-9.
56. Egerer M, Giesemann T, Jank T, Satchell KJ, Aktories K. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem 2007;282:25314-21. Epub 2007 Jun 25.
57. Sheahan KL, Cordero CL, Satchell KJ. Autoprocessing of the Vibrio cholerae RTX toxin by the cysteine protease domain. EMBO J 2007;26:2552-61.
58. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998;49:375-90.
59. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007;55:495-501.
60. Delmee M, Homel M, Wauters G. Serogrouping of Clostridium difficile strains by slide agglutination. J Clin Microbiol 1985;21:323-7.
61. Delmée M, Avesani V. Virulence of ten serogroups of Clostridium difficile in hamsters. J Med Microbiol 1990;33:85-90.
62. Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 2007;28:932-40.
63. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I, on behalf of the European Study Group on Clostridium difficile (ESGCD)*Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clinical Microbiology and Infection 2007;13:1048-57.
64. Rafii F, Wynne R, Heinze TM, Paine DD. Mechanism of metronidazole- resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett 2003;225:195-200.
65. Read RC. Editorial commentary: Vancomycin for your mother, metronidazole for your mother-in-law. J Infect 2007;55:483.
66. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 2007;26:767-78.
67. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
68. http://www.mhp-verlag.de/bilder/awmf_cd.pdf.
69. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64.
70. Elliott B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea. Intern Med J 2007;37:561-8.
71. Clabots CR, Gerding SJ, Olson MM, Peterson LR, Gerding DN. Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989;27:2386-7.